Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$13.26M$13.26M+76.0% vs Q1 2019 Net Income-$3.60M-$3.60MN/M vs Q1 2019 EPS Diluted-$0.07-$0.07N/M vs Q1 2019 Operating Income-$3,856,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$17,058,000N/M Margins · derivedOperating margin-29.1%+112.7 pt vs Q1 2019
Net margin-27.1%+110.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 11, 2020 · 41 d after period end